Mixed Glioma
9
0
0
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
22.2%
2 terminated out of 9 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma